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The biochemical details of the platelet surface as they relate to normal platelet function have
been elucidated through study of labeled membranes from both normal platelets and those with
congenitally defective function. Several cytoadhesive glycoprotein complexes which are integral
components of the platelet membrane have been demonstrated to act as important receptors for
extracellular matrix macromolecules. Glycoproteins Ia/Ila (collagen receptor), Ic/IIa (fibronec-
tin receptor), and Ilb/IlIa (fibrinogen receptor) belong to a family of cytoadhesive complexes
called the integrins, while glycoprotein Ib/IX, the major von Willebrand receptor, has different
features. These same major glycoproteins comprise all of the alloantigens and most of the
autoantigens that have been characterized. Glycoprotein Ilb/IIIa contains the alloantigens, pIA
(Zw), Bak (Lek), and Pen (Yuk), as well as the most frequent target antigenic sites for
anti-platelet autoantibodies. Because a number ofplatelet alloantigens were discovered indepen-
dently by more than one group, nomenclature is confusing at present, although a system
analogous to that used for histocompatibility antigens has been proposed. Precise identification of
the antigenic epitopes has not yet been accomplished for all of the platelet antigens. Current
research efforts include characterization of antigenic epitopes, elucidation of mechanisms by
whichplateletimmunizationoccurs, anddetermination oftheclinical implications ofthepresence
ofvarious platelet antibodies.
BACKGROUND
Platelets are the key blood cells which participate in primary hemostasis. Under
baseline conditions, they glide smoothly over the intact vascular interior, yet, upon
interruption of the vascular endothelium, they interact promptly to form an inter-
twined platelet plug. Abnormalities of this primary hemostatic system can lead to a
serious hemorrhagic state or to excessive thrombosis and vascular insufficiency.
Advances in understanding platelet function and thrombopathic syndromes have
resulted from studies of the major component glycoproteins of the platelet plasma
membrane. This report will summarize our current view of platelet glycoproteins and
their role in clinically important processes.
The early investigations in this area were aimed at identifying specific component
proteins after proteolytic digestion of intact platelets [1,2] or gel electrophoresis and
staining of the carbohydrate-containing components [3,4]. The three groups ofglyco-
proteins first noted were termed glycoproteins (GPs) I, II, and III. Approaches which
have contributed to our current understanding of platelet membrane proteins have
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FIG. 1. Autoradiogram of surface radioiodin-
ated plateletmembranesseparated bytwo-dimen-
sional SDS polyacrylamide gel electrophoresis.
Glycoprotein IlIa appearsabovethediagonal since
its apparent molecular weight increases after di-
sulfide reduction. Glycoproteins such as lb lose a
~;IE 1|11 1111 _ Idisulfide-linked fragment (GPIb,) upon reduc- tion; therefore, GPIba appears below the diago- _R0.gt~~~~~~~~~nal.
included radiolabeling of intact platelets, followed by gel electrophoresis to separate
the labeled components, characterization of defective platelet membranes from pa-
tients with congenital thrombopathies, and creation ofmonoclonal antibodies directed
against platelet surface components. Figure 1 is an autoradiogram of radioiodinated
platelet membranes which have been separated by two-dimensional SDS gel electro-
phoresis. Separation in the first dimension was performed with disulfide bonds intact.
After reduction of these linkages, separation in the second dimension resulted in
improved resolution ofnearby bands. The major components ofthe platelet membrane
are listed in Table 1 and shown in diagrammatic form in Fig. 2.
Considerable refinement ofthe details ofplatelet surface structure has been accom-
plished over the past 20 years, and the system ofnomenclature has been expanded from
the original GPI, GPII, and GPIII to include the glycoproteins listed in Table 1. For
reviews in moredepth, see [6-9]. This summary will focus primarily on the stateofour
current understanding of the platelet membrane, particularly in relation to normal
platelet function, congenital defects of platelets, and the role of antibodies against






Name Nonreduced Reduction Membrane Function
GPIa 155 170 GPIa/IIa Collagen receptor
GPIb 170 170 GPIb/IX von Willebrand factor receptor
GPIc 150 150 GPIc/IIa Fibronectin receptor
GPIIa 130 145 GPIa/IIa; Collagen receptor; Fibronectin receptor
GPIc/IIa
GPIIb 145 145 GPIIb/IIIa Fibrinogen receptor
GPIIIa 95 115 GPIIb/IIIa Fibrinogen receptor
GPIV 95 95 Thrombospondin receptor
(or GPIIIb)
GPV 80 80 Cleaved by thrombin





FIG. 2. A. Glycoprotein IIb/IIIa. The approximate locations of epitopes defining the alloantigen
systems, plA, Pen, and Bak, are indicated, as aresites ofcleavage bytrypsin (T) andchymotrypsin (Cl).
Reprinted with permission from [5]. B. Glycoproteins Ib-IX and V. The approximate locations of
epitopes defining the pIE and pIT alloantigen systems are indicated, along with sites of cleavage by
serratia protease (SP), trypsin (T), and plateletcalpain (Cip). Reprinted with permission from [5].
THE PLATELET MEMBRANE GLYCOPROTEINS: CHARACTERISTICS
AND DEFICIENCIES
Platelet Adhesion, Activation, andAggregation
The main roleofplatelets in the hemostatic system is toprovide the initial protection
from hemorrhage upon interruption ofvascular integrity. Thus, whenever the continu-
ous interior layer ofvascular endothelium is interrupted, platelets become attached to
the exposed subendothelium. The linkage site on the platelet is GPIb, a 170 kDa
platelet protein with a large amount ofsialic acid. A plasma protein, von Willebrand's
factor, acts as a bridge between platelet GPIb and the subendothelial matrix. This
initial phase of primary hemostasis is specifically called "adhesion." After platelet
adhesion occurs, the platelets contract their shape, extending pseudopods of plasma
membrane, and become activated. Platelet "activation" refers to the transferral ofthe
surface signal to generation of arachadonic acid within the platelet, production of
prostaglandins, and the release of granule contents (including ADP, Ca++, and
serotonin) into the exterior milieu. These substances act as agonists to draw more
platelets into the area and facilitate the platelet-to-platelet interactions called platelet
"aggregation." The two glycoproteins, GPIIb and GPIIIa, exist as a complex within
the platelet membrane. In the presence ofcalcium, theGPIIb/IIIa complex undergoes
a conformational change to become a receptor for fibrinogen. The biochemical
bridging interaction ofplatelet-fibrinogen-platelet via the GPIIb/IIIa receptors is the
essential step in platelet aggregation.
Bernard-Soulier syndrome is a rare autosomal recessive defect in platelets, leading
to recurrent hemorrhage from mucous membranes and at sites of trauma. The
associated moderate to severe thrombocytopenia can suggest a diagnosis ofidiopathic
thrombocytopenic purpura (ITP), unless the peripheral blood smear is examined, for
theplatelets in Bernard-Soulier syndrome aregiant platelets with a diameter similar to
that of a small lymphocyte. These platelets lack the ability to adhere to exposed
endothelium [10], and are deficient in the platelet receptor for adhesion, GPIb [11].
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GPIb exists in the normal platelet membrane as a heterodimeric complex with GPIX;
this glycoprotein is also absent from Bernard-Soulier platelets, as is GPV. A diagnosis
of Bernard-Soulier syndrome is supported by the failure of these platelets to undergo
ristocetin-induced agglutination. Confirmation should be made by failure to interact
with monoclonal antibodies specific for GPIb or GPIX.
Glanzmann's thrombasthenia is another congenital abnormality ofplatelet function
which has an autosomal recessive pattern of inheritance. Clinical manifestations are
those of recurrent, often severe, hemorrhage. Platelet count and appearance are
normal, but the bleeding time is prolonged and clot retraction is absent. These platelets
fail to aggregate in response to an agonist and are lacking in the GPIIb/IIIa complex,
the fibrinogen receptor involved in normal platelet aggregation.
The Integrin Family
The GPIIb/IIIa complex serves as a model member of an important group of
cytoadhesive proteins, the integrin family. These receptor protein complexes occur on a
wide variety of cell types, including endothelial cells, fibroblasts, lymphocytes, and a
number of cultured cell lines. The proteins in this family are composed of two (alpha
and beta) subunits. The number of glycoprotein complexes belonging to the integrin
family continues to expand as the cytoadhesive properties ofother cells are character-
ized.
In addition to GPIIb/IIIa, two other platelet glycoprotein complexes belong to the
integrin family. Glycoprotein Ia/IIa forms a receptor for collagen. The GPIa portion
has been shown to be absent from a patient with defective platelet aggregation in the
presence of collagen [12]; this patient had a normal bleeding time and no history of
excessive bleeding. TheGPIc/IIa complex forms a receptor for fibronectin.
Other Glycoproteins
Other proteins of the platelet membrane to which a role in platelet function have
been ascribed includeGPIV, a receptor forthrombospondin [13], and a 40 kDa protein
which acts as a platelet Fc receptor [14]. The platelet receptors for complement, ADP,
and epinephrine have not yet been identified. Thrombin activation ofplatelets cleaves
GPV, but there may be a different receptor for thrombin mediated platelet aggrega-
tion.
The glycoprotein, GMP 140 [15], also called PADGEM protein [16], can serve as a
marker for platelet activation. Present in the alpha granules of resting platelets, this
protein is found on the platelet surface only after activation, when granule membranes
fuse with the plasma membrane. Initially identified on platelets which were activated
in vitro, quantitation ofGMP 140 on freshly drawn platelets is now being studied as a
possible marker for vascular disease.
PLATELET GLYCOPROTEIN TARGETS OF ANTI-PLATELET
ANTIBODIES
Introduction and Terminology
Antibodies against platelet surface components are important in the etiology of
thrombocytopenias, in contributing to refractoriness to platelet transfusion, and as
tools in basic platelet research. Xenoantigens, those identified by antibodies raised in




Name Glycoprotein Proposed HPASystem
PlA, Zw GPIIIa (HPA-1)
Ko, Sib GPIb (HPA-2)
Bak, Lek GPIIb (HPA-3)
Pen, Yuk GPIIIa (HPA-4)
Br, Zav, Hc GPIa (HPA-5)
PIE GPIb ?
PIT GPV ?
have been well defined, as well as rabbit polyclonal antisera which have been valuable
as precipitins for crossed immunoelectrophoresis. Isoantibodies are formed by an
individual whose platelets arecongenitallydeficient inthetargetprotein uponexposure
to normal platelets. For example, a patient with Bernard-Soulier syndrome may form
anti-GPIb/IX isoantibodies after transfusion with normal platelets. Alloantibodies, in
contrast, are those which identify different allelic epitopes present on normal platelets.
plAl and plA2 are allelic forms ofGPIIIa. Ifan individual with pjA2 (i.e., PlAl-negative)
platelets is exposed to platelets that are PlAl-positive, anti-PlAl alloantibodies may
form. The antibodies which are involved in the etiology of ITP are autoantibodies.
They are directed against the individual's own platelets; their antigenic targets are
autoantigens. Alloantigens and autoantigens are those most involved in clinically
important thrombocytopenias; they will be summarized here. Xenoantigens and
isoantigens will not bediscussed further.
Alloantigens
The clinically important alloimmune thrombocytopenias include neonatal alloim-
mune thrombocytopenia and post-transfusion purpura. The clinical features and
immunology of both have been reviewed recently [17] and will not be included here.
Antibodies against the plA1 antigen have been implicated most frequently in both of
thesesyndromes; however, theotheralloantigens listed inTable 2 may beinvolved in at
least an equal number of cases. Note that the reported terminology is very cumber-
some. With theexception ofplA, plE,and pIT, theseantigens have been named after the
last name of the patient in whom the incompatibility was first observed. Not surpris-
ingly, separate reports ofantigens which were later demonstrated to be identical have
led to synonymous terminology for plA (Zw), Bak (Lek), Pen (Yuk), and Br (Zav). At
a recent international platelet immunologysymposium [18], a simplified nomenclature
system was proposed, based upon the HLA terminology. These tentative names are
indicated in Table 2 in parentheses.
Autoantigens
The targets ofantibodies identified from patients with autoimmune thrombocytope-
nia are autoantigens. These antigens have been found to be "public" antigens, present
upon normal platelets from many individuals. The GPIIb/IIIa complex [19], particu-
larly GPIIIa [20], has been the most frequently observed target protein for the
autoantibodies; however, GPIb, GPV, GPIIb, and other platelet glycoproteins have
also been reported (for a review, see [21]). Studies are currently under way to
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determine whether antibodies against a particular platelet glycoprotein will be corre-
lated with a specific clinical course.
CLINICAL IMPLICATIONS OF OUR UNDERSTANDING OF THE
PLATELET GLYCOPROTEINS
Our understanding of the platelet glycoproteins has grown rapidly since the early
1970s, when GPI, GPII, and GPIII were first identified by the new technique of gel
electrophoresis. Knowledge of the molecular defects which lead to Bernard-Soulier
syndrome and Glanzmann's thrombasthenia open the possibility of anti-thrombotic
therapies designed to produce a very mild version of one of these hemorrhagic states.
The fact that GPIb/IX and GPIIb/IIIa are so important for normal platelet function
suggests that the preparation and storage processes involved in providing platelet
products for transfusion should preserve the presence ofthese glycoproteins in order to
assure functional platelets for the transfusion recipient.
Characterization of the platelet alloantigens makes possible typing of platelets and
other blood products for those patients who are demonstrated to suffer from one ofthe
syndromes of alloimmunization. It is also theoretically possible to create a panel of
typed platelets for use in platelet cross-matching; however, the importance of these
platelet glycoprotein-associated alloantigens in transfusion refractoriness has not yet
been established. Anti-HLA antibodies are certainly a more important cause of
transfusion resistance.
The complete biochemical composition of the platelet membrane has not yet been
determined. As our understanding increases, we will certainly find new possibilities for
maintaining a normal hemostatic state in spite of the many perturbations which can
arise in diseases involving blood platelets.
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